XPC and gastric cancer: There was no evidence of significant association between XPC Lys939Gln polymorphism and gastric cancer risk when all the eligible studies were pooled into the meta-analysis (Gln/Gln vs. Lys/lys: OR = 1.123, 95% CI = 0.881–1.431, P = 0.349; Gln/Lys vs. Lys/lys: OR = 1.083, 95% CI = 0.917–1.277, P = 0.347; Gln/Gln + Gln/Lys vs. Lys/lys: OR = 1.092, 95% CI = 0.933–1.277, P = 0.273, Figure 1; Gln/Gln vs. Gln/Lys + Lys/lys: OR = 1.046, 95% CI = 0.838-1.307, P = 0.691).